CONTACT US
Home > Inhibitors/Agonists> > Ivabradine oxalate
1086026-42-7-Ivabradine oxalate Ivabradine oxalate

Ivabradine oxalate

For research use only. Not for therapeutic Use.

  • CAT Number: I029674
  • CAS Number: 1086026-42-7
  • Molecular Formula: C29H38N2O9
  • Molecular Weight: 558.63
  • Purity: 98%
Inquiry Now
Related Small Molecules: Ganoderic Acid C6     AMG131     Calcineurin autoinhibitory peptide    

Ivabradine oxalate is a bradycardic agent.


Catalog Number I029674
CAS Number 1086026-42-7
Synonyms

Ivabradine oxalate

Molecular Formula C29H38N2O9
Purity 98%
Solubility To be determined
Appearance Solid powder
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name 2H-3-Benzazepin-2-one, 3-(3-((((7S)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, ethanedioate (1:1)
InChI InChI=1S/C27H36N2O5.C2H2O4/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;3-1(4)2(5)6/h12-14,16,21H,6-11,15,17H2,1-5H3;(H,3,4)(H,5,6)/t21-;/m1./s1
InChIKey BOHZBFAHOBOJOS-ZMBIFBSDSA-N
SMILES COc1cc2CCN(CCCN(C)C[C@H]3Cc4cc(OC)c(OC)cc34)C(=O)Cc2cc1OC.OC(=O)C(=O)O
Reference

1: Ide T, Ohtani K, Higo T, Tanaka M, Kawasaki Y, Tsutsui H. Ivabradine for the Treatment of Cardiovascular Diseases. Circ J. 2019 Jan 25;83(2):252-260. doi: 10.1253/circj.CJ-18-1184. Epub 2018 Dec 29. PMID: 30606942.
2: Bocchi EA, Salemi VMC. Ivabradine for treatment of heart failure. Expert Opin Drug Saf. 2019 May;18(5):393-402. doi: 10.1080/14740338.2019.1612873. Epub 2019 May 10. PMID: 31074301.
3: Komajda M. Ivabradine. Handb Exp Pharmacol. 2017;243:167-175. doi: 10.1007/164_2016_55. PMID: 27752846.
4: Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The Clinical Use of Ivabradine. J Am Coll Cardiol. 2017 Oct 3;70(14):1777-1784. doi: 10.1016/j.jacc.2017.08.038. PMID: 28958335.
5: Chiu MH, Howlett JG, Sharma NC. Initiation of ivabradine in cardiogenic shock. ESC Heart Fail. 2019 Oct;6(5):1088-1091. doi: 10.1002/ehf2.12499. Epub 2019 Jul 23. PMID: 31332966; PMCID: PMC6816060.
6: Dallapellegrina L, Sciatti E, Vizzardi E. Ivabradine and endothelium: an update. Ther Adv Cardiovasc Dis. 2020 Jan-Dec;14:1753944720934937. doi: 10.1177/1753944720934937. PMID: 32611276; PMCID: PMC7333483.
7: Tsutsui H, Momomura SI, Yamashina A, Shimokawa H, Kihara Y, Saito Y, Hagiwara N, Ito H, Yano M, Yamamoto K, Ako J, Inomata T, Sakata Y, Tanaka T, Kawasaki Y; J-SHIFT Study Investigators. Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure　- J-SHIFT Study. Circ J. 2019 Sep 25;83(10):2049-2060. doi: 10.1253/circj.CJ-19-0227. Epub 2019 Aug 8. PMID: 31391387.
8: Zhou Y, Wang J, Meng Z, Zhou S, Peng J, Chen S, Wang Q, Sun K. Pharmacology of Ivabradine and the Effect on Chronic Heart Failure. Curr Top Med Chem. 2019;19(21):1878-1901. doi: 10.2174/1568026619666190809093144. PMID: 31400267.
9: Pei H, Miao W, Xie WZ, Wang W, Zhao D, Su GH, Zhao Z. Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure. Int Heart J. 2019 Jul 27;60(4):899-909. doi: 10.1536/ihj.18-559. Epub 2019 Jul 12. PMID: 31308326.
10: Simko F, Baka T, Poglitsch M, Repova K, Aziriova S, Krajcirovicova K, Zorad S, Adamcova M, Paulis L. Effect of Ivabradine on a Hypertensive Heart and the Renin-Angiotensin-Aldosterone System in L-NAME-Induced Hypertension. Int J Mol Sci. 2018 Oct 3;19(10):3017. doi: 10.3390/ijms19103017. PMID: 30282928; PMCID: PMC6212851.

Request a Quote